The risk of dyspnea in patients treated with third-generation P2Y inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials.
Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial.
Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis.
Ticagrelor-related late-onset dyspnea as cause of emergency department visit: a 3-year outpatient study.
Dyspnea in patients treated with P2Y receptor antagonists: insights from the GReek AntiPlatElet (GRAPE) registry.
Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial.
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Ticagrelor related dyspnea in patients with acute coronary syndromes: Incidence and implication on ticagrelor withdrawn.
'Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel' - a hypothesis that remains unproven.
Viewpoint: reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel.
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.
Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.